This Is A Guide To GLP1 Drugs Germany In 2024

April 19, 2026

The Evolution of GLP-1 Drugs in Germany: A Comprehensive Guide to Treatment, Regulation, and Availability

In current years, the pharmaceutical landscape in Germany has undergone a significant shift with the arrival and rapid adoption of GLP-1 receptor agonists (GLP-1 RAs). Originally established to handle Type 2 diabetes, these medications— recognized informally by brand like Ozempic and Wegovy— have actually gotten international popularity for their efficacy in weight management. Nevertheless, the German health care system, known for its rigorous regulatory requirements and structured insurance coverage structures, supplies an unique context for the distribution and usage of these drugs.

This short article takes a look at the existing state of GLP-1 drugs in Germany, exploring their medical benefits, the regulatory obstacles they deal with, and the usefulness of expense and insurance coverage.

What are GLP-1 Drugs?

Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in the intestines. It plays a crucial role in glucose metabolism by promoting insulin secretion, inhibiting glucagon release, and slowing stomach emptying. GLP-1 receptor agonists are synthetic versions of this hormone developed to last longer in the body.

In Germany, these drugs are mainly prescribed for two signs:

Type 2 Diabetes Mellitus: To improve glycemic control.
Weight problems Management: To assist in weight reduction in patients with a high Body Mass Index (BMI) or weight-related comorbidities.

The Landscape of GLP-1 Medications in Germany

The German market functions numerous crucial players in the GLP-1 area. While some have been offered for over a decade, the brand-new generation of weekly injectables has caused a surge in need.

Contrast of Major GLP-1 and Dual-Agonist Drugs in Germany

Brand name Name

Active Ingredient

Manufacturer

Main Indication

German Launch/Status

Ozempic

Semaglutide

Novo Nordisk

Type 2 Diabetes

Readily available

Wegovy

Semaglutide

Novo Nordisk

Weight problems Management

Launched July 2023

Mounjaro

Tirzepatide

Eli Lilly

T2D & & Obesity

Readily available

Saxenda

Liraglutide

Novo Nordisk

Weight problems Management

Available

Victoza

Liraglutide

Novo Nordisk

Type 2 Diabetes

Offered

Trulicity

Dulaglutide

Eli Lilly

Type 2 Diabetes

Available

Keep In Mind: Tirzepatide (Mounjaro) is a double GIP/GLP -1 receptor agonist, typically organized with GLP-1s due to its similar mechanism and use.

Regulative Framework and BfArM Guidance

In Germany, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte or BfArM) oversees the security and supply of medications. The abrupt global demand for semaglutide resulted in substantial local lacks, prompting BfArM to provide rigorous standards.

Attending to the Shortage

To safeguard patients with Type 2 diabetes, BfArM has actually consistently advised physicians and pharmacists to prioritize the dispensing of products like Ozempic for its authorized diabetic sign. Making use of diabetes-specific GLP-1 drugs for “off-label” weight loss has actually been strongly dissuaded to make sure that lifesaver medication remains offered for those with metabolic disorders.

The G-BA and Reimbursement

The Federal Joint Committee (Gemeinsamer Bundesausschuss or G-BA) identifies which medical services are covered by statutory health insurance (GKV). This is a critical element in Germany, as it dictates whether a patient pays a small co-pay or the full market cost.

Insurance Coverage Coverage and Costs in Germany

The expense of GLP-1 treatment in Germany depends largely on the patient's insurance type and the specific medical diagnosis.

Statutory Health Insurance (Gesetzliche Krankenkasse)

Diabetes: If a client is diagnosed with Type 2 diabetes, the Krankenkasse normally covers the cost of GLP-1 drugs (like Ozempic or Mounjaro). The client usually just pays a small statutory co-payment (Zuzahlung) of EUR5 to EUR10.
Weight problems: Under present German law (the “Lifestyle Drug” paragraph, § 34 SGB V), medications mainly meant for weight-loss— such as Wegovy or Saxenda— are normally omitted from compensation by statutory health insurance companies. This stays a point of extreme political and medical dispute in Germany.

Private Health Insurance (Private Krankenversicherung)

Private insurance providers in Germany operate under various rules. Numerous personal strategies cover Wegovy or Mounjaro for weight loss if the client fulfills specific requirements (e.g., a BMI over 30 or a BMI over 27 with comorbidities like hypertension). However, patients are advised to get a cost-absorption declaration (Kostenübernahmeerklärung) from their supplier in advance.

Self-Pay Prices

For those paying out of pocket, the expenses are significant. As of late 2023 and early 2024, the month-to-month cost for Wegovy in Germany varies from roughly EUR170 to EUR300, depending on the dosage.

Medical Benefits and Side Effects

While the weight-loss results— often ranging from 15% to 22% of body weight in medical trials— are remarkable, these drugs are not without risks.

Common Side Effects

Many clients experience gastrointestinal issues, particularly during the dose-escalation stage:

Nausea and vomiting.
Diarrhea or constipation.
Stomach discomfort and bloating.
Heartburn (GERD).

Major Considerations

Pancreatitis: An uncommon but major inflammation of the pancreas.
Gallbladder concerns: Increased danger of gallstones.
Muscle Loss: Rapid weight reduction can result in a reduction in lean muscle mass if not accompanied by resistance training and adequate protein intake.
- *

The Prescription Process in Germany

Acquiring GLP-1 drugs in Germany needs a rigorous medical protocol. They are not available “non-prescription” and require a prescription from a certified doctor.

Preliminary Consultation: A GP or Endocrinologist examines the patient's case history, BMI, and blood markers (HbA1c).
Medical diagnosis: The doctor figures out if the patient fulfills the criteria for diabetes or scientific obesity.
Prescription Type:
- Pink Prescription (Kassenrezept): For statutory insurance coverage (diabetes).
- Blue/White Prescription (Privatrezept): For private insurance coverage or self-payers (obesity).
Pharmacy Fulfillment: Due to shortages, clients might need to call numerous pharmacies to find stock, specifically for higher doses.

Future Outlook: The Pipeline and Policy Changes

The German medical community is closely looking for legal changes. There is a growing motion of medical associations (such as the Deutsche Adipositas-Gesellschaft) advocating for obesity to be recognized as a persistent illness, which would require statutory insurance providers to cover treatment.

Furthermore, brand-new drugs are on the horizon. Retatrutide (a triple agonist) is currently in clinical trials and guarantees even higher weight-loss effectiveness. As more competitors get in the German market, it is anticipated that supply chain issues will support and rates might ultimately reduce.

Regularly Asked Questions (FAQ)

1. GLP-1 bestellen in Deutschland offered in Germany?

Yes, Wegovy was officially launched in Germany in July 2023. It is readily available for adult clients with a BMI of 30 or higher, or 27 or greater with a minimum of one weight-related disorder.

2. Can I get Ozempic for weight reduction in Germany?

While a physician can technically write a private prescription for Ozempic off-label, German health authorities (BfArM) have actually limited this practice to ensure supply for diabetic patients. Doctors are motivated to recommend Wegovy rather for weight-loss purposes.

3. Does the “Krankenkasse” spend for weight reduction injections?

Generally, no. Under existing German law, drugs for weight-loss are categorized as “way of life medications” and are not covered by statutory health insurance coverage, even if clinically needed. Coverage is usually just given for the treatment of Type 2 Diabetes.

4. How much weight can I expect to lose?

In clinical trials, clients using high-dose semaglutide (Wegovy) lost approximately 15% of their body weight over 68 weeks. Those on tirzepatide (Mounjaro) have actually seen losses of approximately 20-22% when integrated with diet and workout.

5. Why is there a lack of these drugs in Germany?

The shortage is brought on by a massive international boost in need that has actually surpassed the manufacturing capacity of business like Novo Nordisk and Eli Lilly. Production facilities are being broadened, but the “Ozempic hype” on social networks has added to provide gaps.

6. Exist oral variations offered in Germany?

Yes, Rybelsus is an oral type of semaglutide. Nevertheless, Mehr erfahren is presently just authorized for the treatment of Type 2 Diabetes in Germany and is typically considered less effective for weight loss than the injectable versions.

Summary List: Key Takeaways

Double Use: GLP-1 drugs serve both diabetic management and weight problems treatment however under various trademark name and guidelines.
Rigorous Regulation: BfArM keeps an eye on supply closely to focus on diabetic patients.
Expense Barrier: Most weight-loss patients in Germany must pay out-of-pocket, costing numerous Euros per month.
Medical Oversight: These are not “simple fix” drugs; they need lifelong management and medical guidance to monitor negative effects.
Insurance coverage Gap: There is a substantial distinction in between statutory (seldom covers weight reduction) and private insurance (might cover weight-loss).

By staying notified about the progressing regulations and accessibility, clients in Germany can much better browse their choices for metabolic and weight-related health.